Gritstone Oncology Inc (GRTS)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

5858 HORTON STREET, SUITE 210 EMERYVILLE, CA 94608

Gritstone Oncology, Inc. produces and distributes pharmaceutical products. The Company offers cancer care drugs to treat tumors. Gritstone Oncology markets its products in the United States.

Data as of 2020-06-27
Market Cap254.147 Million Shares Outstanding37.265 Million Avg 30-day Volume307.073 Thousand
P/E Ratio Dividend Yield EPS-2.88
Price/Sales59.38 Price cash flow ratio Price free cash flow ratio-2.5
Book Value3.1 Price to Tangible Book2.23 Alpha
Short Interest Ratio % Short Interest to Float R-squared
BETA 52-week High/Low12.96 / 5.42 Stddev
View SEC Filings from GRTS instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 0 (0.0%)
13F Filers holding this stock: 66 15 (0.98%)
Aggregate 13F shares on 03/31/2020: 28.919 Million 12.56 Million
Aggregate 13F shares on 12/31/2019: 28.306 Million 12.277 Million
Percent change: 2.17% 2.30%
Funds creating new positions: 13 5
Funds Adding to an existing position: 21 6
Funds closing out their position: 3 2
Funds reducing their position: 17 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GRTS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GRTS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WOIWODE THOMAS

  • Director
0 2020-06-23 1

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
1,586,174 2020-06-23 0

HEYMAN RICHARD A.

  • Director
0 2020-06-18 1

SVENNILSON PETER

  • Director
  • 10% Owner
0 2020-06-18 0

SIMON NICHOLAS

  • Director
  • 10% Owner
0 2020-06-18 1

LI JUDITH

  • Director
0 2020-06-18 1

KROGNES STEVE E.

  • Director
0 2020-06-18 1

JONES ELAINE V

  • Director
0 2020-06-18 3

ALLEN ANDREW R

  • Director
0 2020-06-09 1

THOMPSON RAHSAAN EVP AND GENERAL COUNSEL

  • Officer
0 2020-05-13 2

JOOSS KARIN

  • Director
0 2020-05-01 1

BELLEMIN JEAN-MARC SEE REMARKS

  • Officer
0 2020-02-25 1

JONES ERIN SEE REMARKS

  • Officer
0 2020-02-25 1

HAWRYLUK MATTHEW SEE REMARKS

  • Officer
0 2020-02-25 1

YELENSKY ROMAN SEE REMARKS

  • Officer
0 2020-02-25 1

ROUSSEAU RAPHAEL SEE REMARKS

  • Officer
0 2020-02-25 2

YABANNAVAR VIJAY SEE REMARKS

  • Officer
0 2020-02-25 3

YELENSKY ROMAN SEE REMARKS

YELENSKY ROMAN SEE REMARKS

  • Officer
0 2019-02-13 1

VERSANT VENTURE CAPITAL V, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT AFFILIATES FUND V, L.P.

  • 10% Owner
  • GENERAL PARTNERGENERAL PARTNERGENERAL PARTNER
3,102,929 2018-10-02 0

COLUMN GROUP II, LP

COLUMN GROUP II GP, LP

SVENNILSON PETER

GOEDDEL DAVID V

  • Director
  • 10% Owner
  • GENERAL PARTNER MANAGING PARTNER
3,102,934 2018-10-02 0

CLARUS LIFESCIENCES III, L.P.

CLARUS VENTURES III GP, L.P.

CLARUS VENTURES III, LLC

  • 10% Owner
  • GENERAL PARTNERGENERAL PARTNER
2,567,445 2018-09-28 0

APHALE JAYANT SEE REMARKS

  • Officer
0 2018-09-27 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

WOIWODE THOMAS - Director - > 10% Owner

2020-06-18 A 12,500 a 12,500 0.00 direct

KROGNES STEVE E. - Director

2020-06-18 A 12,500 a 12,500 0.00 direct

HEYMAN RICHARD A. - Director

2020-06-18 A 12,500 a 12,500 0.00 direct

LI JUDITH - Director

2020-06-18 A 12,500 a 12,500 0.00 direct

SIMON NICHOLAS - Director - > 10% Owner

2020-06-18 A 12,500 a 12,500 0.00 direct

JONES ELAINE V - Director

2020-06-18 A 12,500 a 12,500 0.00 direct

THOMPSON RAHSAAN - Officer EVP AND GENERAL COUNSEL

2020-05-13 A 85,000 a 85,000 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments